Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Insider Arturo Md Molina Sells 26,000 Shares

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) insider Arturo Md Molina sold 26,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $44.70, for a total transaction of $1,162,200.00. Following the completion of the transaction, the insider now directly owns 46,444 shares in the company, valued at $2,076,046.80. This trade represents a 35.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Arturo Md Molina also recently made the following trade(s):

• On Friday, November 15th, Arturo Md Molina sold 1,906 shares of Protagonist Therapeutics stock. The stock was sold at an average price of $40.98, for a total transaction of $78,107.88.

Protagonist Therapeutics Stock Up 0.3 %

Protagonist Therapeutics stock opened at $44.95 on Friday. The firm has a fifty day moving average of $45.22 and a 200-day moving average of $39.66. The firm has a market capitalization of $2.68 billion, a P/E ratio of 16.90 and a beta of 2.17. Protagonist Therapeutics, Inc. has a 52-week low of $17.13 and a 52-week high of $48.89.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Farallon Capital Management LLC boosted its stake in Protagonist Therapeutics by 1.8% during the 2nd quarter. Farallon Capital Management LLC now owns 5,840,773 shares of the company’s stock valued at $202,383,000 after acquiring an additional 101,800 shares during the last quarter. RTW Investments LP lifted its position in shares of Protagonist Therapeutics by 2.6% in the 3rd quarter. RTW Investments LP now owns 5,426,112 shares of the company’s stock worth $244,175,000 after buying an additional 139,708 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Protagonist Therapeutics by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 3,192,971 shares of the company’s stock worth $92,373,000 after buying an additional 39,055 shares during the last quarter. State Street Corp lifted its position in shares of Protagonist Therapeutics by 52.9% in the 3rd quarter. State Street Corp now owns 3,183,542 shares of the company’s stock worth $143,259,000 after buying an additional 1,101,218 shares during the last quarter. Finally, Pacer Advisors Inc. lifted its position in shares of Protagonist Therapeutics by 405,061.2% in the 3rd quarter. Pacer Advisors Inc. now owns 1,734,090 shares of the company’s stock worth $78,034,000 after buying an additional 1,733,662 shares during the last quarter. 98.63% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Truist Financial began coverage on shares of Protagonist Therapeutics in a report on Monday, September 9th. They issued a “buy” rating and a $60.00 target price for the company. StockNews.com raised shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Protagonist Therapeutics in a research report on Tuesday, November 19th. JMP Securities reduced their price target on shares of Protagonist Therapeutics from $45.00 to $43.00 and set a “market outperform” rating for the company in a research report on Wednesday, August 7th. Finally, Wedbush restated an “outperform” rating and issued a $58.00 price objective on shares of Protagonist Therapeutics in a research note on Tuesday, November 19th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $53.57.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.